摘要
目的检测转录信号传导与转录激活因子3(STAT3)、细胞周期素D1(CyclinD1)在皮肤恶性黑色素瘤(CMM)中的表达及其与病理特征的关系。方法采用免疫组织化学链霉菌抗生物素蛋白一过氧化物酶(sP)法检测78例CMM、24例交界痣、22例正常皮肤组织中STAT3、CyclinD1的表达水平。结果(1)STAT3蛋白在CMM、皮肤交界痣和正常皮肤中阳性表达率分别为57.7%、29.2%、18.2%。CMM与皮肤交界痣、正常皮肤比较差异有统计学意义(P〈0.05)。(2)CyclinD1蛋白在CMM、皮肤交界痣和正常皮肤中阳性表达率分别为62.8%、33.3%、27.3%。CMM与皮肤交界痣、正常皮肤比较差异有统计学意义(P〈0.05)。(3)STAT3表达与CyclinD1表达呈正相关(P〈0.01,r=0.533);(4)STAT3与CyclinD1在CMM中的表达阳性率均随其浸润深度的增加而增高,且有淋巴结转移的阳性率表达高于无淋巴结转移,差异均有统计学意义(P〈0.叭)。结论STAT3、CyclinD1蛋白可能促进CMM的发生、浸润和淋巴转移;两者之间可能具有协同作用。
Objective To explore the expression of signal transducers and activators of transcrip- tion (STAT3), Cyclin D1 in cutaneous malignant melanoma (CMM) and relationship between them with pathological features. Methods The SP immunohistochemical technique was used to detect the expression of STA33, Cyclin D1 in 78 case CMM, 24 case mole skin junction and 22 case of normal skin. Results ( 1 )Their positive expression of STA33 in CMM is 57.7%. There were low expression in mole skin junc- tion or normal skin, their positive expression were 29.2% , 18.2%. There was a statistical significance be- tween the CMM and mole skin junction or normal skin ( P 〈 0. 05 ). ( 2 ) Their positive expression of Cyclin D1 in CMM is 62. 8%. There were low expression in mole skin junction or normal skin, their posi- tive expression were 33.3%, 27.3%. There was a statistical significance between the CMM and mole skin junction or normal skin ( P 〈 0. 05 ). ( 3 ) The expressions of STAT3 and Cyclin D1 in CMM was positively associated (P 〈 0. 01, r = 0. 533 ). (4)The positive rate of STA33 and Cyclin D1 in CMM increased along with the depth of infiltration, the positive rate withlymphatic metastasis were higher. There was a statistical significance between them(P 〈 0. 01 ). Conclusion STAT3 and Cyclin D1 protein may play a positive role in the occurrence,infiltration and lymphatic metastasis of CMM. There may be a synergistic effect be- tween them.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2016年第8期2016-2018,共3页
Chinese Journal of Experimental Surgery
基金
宜昌市卫生科技项目(A15301-23)